ALGS 8-K 2026-09-15

Aligos Therapeutics, Inc. (ALGS) 8-K dated 2026-09-15 — accession 0001193125-26-391880. This URL is the filing, not the ALGS hub.

Aligos Therapeutics, Inc. (ALGS) is a biotechnology company listed on US.

Aligos Therapeutics, Inc. filed a 8-K on 2026-09-15. Accession 0001193125-26-391880.

Cached items: 1.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported ALGS revenue for 2025-12-31 was $2.2M. Net income was -$24.2M. Revenue was down 39.5% from 2024-12-31 to 2025-12-31. ALGS currently screens at market cap $44.1M.

Not investment advice. The ALGS SEC hub lists recent forms. The stock page is the research view.